Compare HOMB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | RYTM |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.3B |
| IPO Year | 2006 | 2017 |
| Metric | HOMB | RYTM |
|---|---|---|
| Price | $29.87 | $107.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $32.88 | ★ $140.12 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 10-14-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 19.90 | ★ 28.34 |
| EPS | ★ 1.84 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.28 | $73.80 |
| Revenue Next Year | $3.19 | $73.86 |
| P/E Ratio | $16.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.50 | $74.50 |
| 52 Week High | $31.70 | $122.20 |
| Indicator | HOMB | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 57.44 |
| Support Level | $29.70 | $106.58 |
| Resistance Level | $30.32 | $111.16 |
| Average True Range (ATR) | 0.57 | 6.96 |
| MACD | -0.05 | 1.57 |
| Stochastic Oscillator | 19.84 | 74.77 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.